Neuromyelitis optica spectrum disorder

The PBS subsidises ravulizumab for patients with neuromyelitis optica spectrum disorder (NMOSD).

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with ravulizumab under the National Health Act 1953, section 100 for patients with NMOSD.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing ravulizumab.

Section 100 arrangements

ravulizumab

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with ravulizumab, patients must be treated by either a:

  • neurologist
  • medical practitioner in consultation with a neurologist.

Authority applications

Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made:

All written applications must include:

Applying for initial grandfather treatment

Please note: You don’t need to complete this application in writing when you request PBS authority online.

Applications for initial grandfather authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made:

All written applications must include:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised ravulizumab to treat NMOSD can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 April 2025.
QC 81013